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Abstract 
Spinal muscular atrophy (SMA) is a neurodegenerative disease associated with severe muscle atrophy and weakness in the limbs and trunk. We 
report interim efficacy and safety outcomes as of March 29, 2019 in 25 children with genetically diagnosed SMA who first received nusinersen in 
infancy while presymptomatic in the ongoing Phase 2, multisite, open-label, single-arm NURTURE trial. Fifteen children have two SMN2 copies and 
10 have three SMN2 copies. At last visit, children were median (range) 34.8 [25.7–45.4] months of age and past the expected age of symptom onset 
for SMA Types I or II; all were alive and none required tracheostomy or permanent ventilation. Four (16%) participants with two SMN2 copies 
utilized respiratory support for ≥6 h/day for ≥7 consecutive days that was initiated during acute, reversible illnesses. All 25 participants achieved 
the ability to sit without support, 23/25 (92%) achieved walking with assistance, and 22/25 (88%) achieved walking independently. Eight infants 
had adverse events considered possibly related to nusinersen by the study investigators. These results, representing a median 2.9 years of follow up, 
emphasize the importance of proactive treatment with nusinersen immediately after establishing the genetic diagnosis of SMA in presymptomatic 
infants and emerging newborn screening efforts. 
© 2019 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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[  . Introduction 
Spinal muscular atrophy (SMA) is an autosomal recessive
eurodegenerative disease associated with progressive and 
ften severe muscle weakness and atrophy and is a leading
ause of death in infants [1–4] . SMA is caused by
omozygous deletions ( ∼95% of SMA patients) or compound
eterozygous mutations ( ∼5% of SMA patients) in the
urvival motor neuron 1 ( SMN1 ) gene that prevent production
f full-length functional SMN protein [5] . The paralogous
ene SMN2 undergoes aberrant splicing and produces mostly
runcated, dysfunctional protein ( ∼90%) [1] . Symptom onset
ost often occurs in infancy and early childhood, although
nset can be in adulthood in the mildest form. Symptoms are
enerally more severe with earlier onset [1] . Most individuals
ho develop SMA have a symptom-free period after birth,
hich differs in duration for every individual. SMA is
ivided into four major subtypes based on age at symptom
nset and maximum motor function achieved [1 , 6 , 7] , but
aximum motor function achievement can be influenced by
MA treatment. Many infants with infantile-onset SMA and
hildren with later-onset SMA treated with nusinersen in
he ENDEAR and CHERISH studies, respectively, achieved
otor function incongruent with their expected SMA subtypes
ased on SMN2 copy number and age of symptom onset [8 , 9] .
Prior to the onset of symptoms, other markers must be
elied upon for diagnosis and classification of predicted SMA
ubtype. SMN2 gene copy number is roughly correlated with
isease severity, as an increased number of SMN2 gene
opies typically leads to an increased amount of functional
MN protein and a milder phenotype [1] . Among individuals
ho have SMN1 disruptions and are therefore expected to
evelop SMA symptoms, approximately 75% of individuals
ith two copies of the SMN2 gene are predicted to develop
he Type I form of SMA, while approximately 80% of
hose with three copies of the SMN2 gene are predicted to
evelop SMA Type II [10 , 11] . Additionally, phosphorylated
eurofilament heavy chain (pNF-H) levels have recently been
hown to be a promising biomarker of disease activity
nd treatment response in individuals with SMA [12 , 13] .
NF-H is a neuron-specific cytoskeletal structural protein
eleased into the plasma and cerebrospinal fluid (CSF) during
xonal damage [14 , 15] . In the ENDEAR and CHERISH
tudies, concentrations of pNF-H were found to correlate
ith baseline clinical characteristics indicative of disease
everity. Furthermore, pNF-H concentrations declined rapidly
hen stabilized at a lower level following nusinersen treatment
n a manner not seen in the sham control group [13] . 
Nusinersen is an antisense oligonucleotide that alters the
plicing of SMN2 pre-mRNA to promote expression of full-
ength SMN protein [7 , 21–23] and is the first disease-∗ Corresponding author. 
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m  odifying treatment approved for SMA [24] . In clinical
tudies in a range of symptomatic children across several
MA populations, nusinersen demonstrated significant and 
linically meaningful benefit as assessed by achievement of
otor milestones, measures of motor function, and survival in
hose with infantile-onset SMA, along with a favorable safety
rofile [8 , 9 , 25] . Importantly, subgroup analyses of the sham-
ontrolled studies in infantile-onset (ENDEAR) and later-
nset (CHERISH) SMA indicated that greater improvements
n motor function following nusinersen treatment were
bserved in those with relatively shorter disease duration at
reatment initiation [8 , 9] , suggesting that earlier treatment
ay lead to better clinical outcomes. 
NURTURE is an ongoing Phase 2, open-label study aimed
o evaluate the safety and efficacy of nusinersen in preventing
r profoundly attenuating the severity of SMA when initiated
rior to the onset of symptoms. Infants enrolled in NURTURE
ad genetic confirmation of 5q SMA, were ≤6 weeks old
t first dose, and were considered most likely to develop
MA Type I or Type II based upon the SMN2 gene copy
umber and the expected concordance with the phenotype of
n affected sibling(s) based on previous studies [10 , 11 , 26] .
n the absence of treatment, many of these infants would not
e expected to achieve independent sitting (those likely to
evelop SMA Type I), and few if any would be expected
o ever walk independently [6] . Most would also be expected
o require respiratory intervention and some would not survive
eyond their early years [27] . 
. Patients and methods 
.1. Study design and participants 
NURTURE (NCT02386553) is an ongoing, Phase 2,
pen-label, single-arm, multinational study to evaluate the
ong-term safety and efficacy of intrathecal nusinersen in
nfants who initiate treatment early, prior to the onset of
linical signs of SMA. Given the expectation that infants with
enetically diagnosed SMA without a functioning copy of the
MN1 gene and with two or three copies of the SMN2 gene
ill develop severe or fatal symptoms during the first years
f life, an internal control group was considered unnecessary
nd ethically unjustifiable. 
NURTURE consists of a 5-year treatment period and a
ost-treatment follow-up evaluation. Key eligibility criteria
ere age ≤6 weeks at first dose, genetic documentation
f 5q SMA (biallelic deletion or protein disabling mutation
f the SMN1 gene), two or three copies of the SMN2
ene, baseline compound muscle action potential (CMAP)
mplitude ≥1 mV (protocol amended on 30 September 2015
version 4] to baseline ulnar CMAP amplitude ≥1 mV),
bsence of hypoxemia, and no clinical signs or symptoms
uggestive of SMA. Participants received nusinersen 12 mg
dministered as intrathecal injections by lumbar puncture. The
usinersen treatment regimen consists of four loading doses
administered on Days 1, 15, 29, and 64), followed by a
aintenance dose every 119 days over five years ( Fig. 1 ).
844 D.C. De Vivo, E. Bertini and K.J. Swoboda et al. / Neuromuscular Disorders 29 (2019) 842–856 
Fig. 1. NURTURE study design. 
Intention-to-treat population is all infants who received ≥1 dose of study drug ( n = 25). 
a Infants who attended or had the opportunity to attend the visit. 
b Infants treated with nusinersen 12 mg; some infants received a 12-mg scaled equivalent dose before the protocol was revised in March 2017. 
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q  This interim analysis from the ongoing NURTURE study
reports data from the March 29, 2019, data cut. At the time of
this interim analysis, the NURTURE infants were 25.7–45.4
(median 34.8) months of age and were past the expected age
of symptom onset for SMA Types I or II [3 , 27] . 
The NURTURE trial is taking place at 15 active study
sites in seven countries. The study was approved by the
local ethics committee at each participating site and is being
conducted in accordance with the International Council on
Harmonization (ICH) guidelines for Good Clinical Practice
and the Declaration of Helsinki. Written informed consent
was obtained from the parent(s) or legal guardian(s) of
each study participant in accordance with local practice and
regulations. 
2.2. Study endpoints reported in this interim analysis 
2.2.1. Primary endpoints 
The primary endpoint for NURTURE is time to death or
respiratory intervention (invasive or non-invasive for ≥6 h per
day continuously for ≥7 days or tracheostomy). 
2.2.2. Secondary endpoints 
Secondary endpoints reported in this interim analysis
include (1) proportion of participants alive; (2) attainment
of motor milestones as assessed by World Health
Organization (WHO) criteria; (3) attainment of motor
milestones by Hammersmith Infant Neurologic Examination,
Section 2 (HINE-2); (4) change from baseline in
the Children’s Hospital of Philadelphia Infant Test of
Neuromuscular Disorders (CHOP INTEND) motor function
scale; (5) change from baseline in growth parameters: weight
for age/length, head circumference, chest circumference,
head-to-chest circumference ratio, and arm circumference;
and (6) proportion of participants developing clinically
manifested SMA at 13 and 24 months of age as defined
by any of the following conditions: (a) age-adjusted weight
< 5th percentile or decrease of ≥2 major weight growth
curve percentiles (3rd, 5th, 10th, 25th, or 50th) compared
with baseline, or a percutaneous gastric tube placement for
nutritional support at 13 or 24 months of age; (b) failure to
achieve sitting without support, standing with assistance, andands-and-knees crawling at age 13 months; or (c) failure
o achieve the milestones defined at age 13 months and
ailure to achieve walking with assistance, standing alone,
nd walking alone at age 24 months. 
Secondary safety endpoints include (1) incidences
f adverse events (AEs) and serious adverse events
SAEs); (2) change from baseline in clinical laboratory
arameters, electrocardiograms (ECGs), and vital signs; and
3) neurological examinations (HINE-1 [neurological status]
nd HINE-3 [behavior] for participants age ≤24 months;
tandard neurological exam for participants age > 24 months).
.2.3. Exploratory endpoints 
Exploratory endpoints, including (1) change from baseline
n CMAP amplitude; (2) time to death or permanent
entilation (defined as ≥16 h/day continuously for > 21 days
n the absence of an acute reversible event or tracheostomy);
3) time to death or ventilation for ≥6 h/day continuously
or ≥1 day or tracheostomy; and (4) plasma and CSF pNF-H
oncentration and change over time were also assessed in this
nterim analysis. 
.3. Assessments 
The following clinical assessments were performed to
valuate nusinersen efficacy: survival, respiratory events,
HO and HINE-2 motor milestone achievement, HINE-
 neurological evaluation, CHOP INTEND motor function
cale, growth parameters, ulnar and peroneal CMAP
mplitudes, and plasma/CSF pNF-H levels. A listing of study
isits at which data was collected for the study assessments
s provided in Supplementary Table 1. 
Achievement of motor milestones was evaluated using
HO criteria [28] and the HINE-2 assessment tool [29] .
HO motor milestones are a set of six milestones (sitting
ithout support, standing with assistance, hands-and-knees
rawling, walking with assistance, standing alone, and
alking alone) expected to be attained by age 24 months
n healthy children [28] . WHO motor milestones were
ssessed by physical therapists; age of first achievement
f each milestone was recorded by caregivers. HINE is a
uantifiable, three-part assessment to evaluate neurological
D.C. De Vivo, E. Bertini and K.J. Swoboda et al. / Neuromuscular Disorders 29 (2019) 842–856 845 
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(  tatus (Section 1), development of motor function (Section 2),
nd behavior (Section 3) [29] . Neurological items assessed
y the HINE-1 include sucking/swallowing ability during
ssessment of cranial nerve function [29] . Scores range from
 to 3, with higher scores indicating better function. HINE-2
easures developmental progress in eight motor milestones:
oluntary grasp, ability to kick in supine position, head
ontrol, rolling, sitting, crawling, standing, and walking. Total
cores range from 0 to 26, with higher scores indicating
etter motor function [29] . The HINE-2 score was assessed
ntil Day 778. CHOP INTEND is a 16-item, 64-point motor
ssessment developed to evaluate motor skills in infants with
MA Type I, with higher scores indicating better motor
unction [30 , 31] . The CHOP INTEND was assessed until a
articipant reached a maximum score of 64, after which it was
ot assessed. Motor function assessments were performed by
rained clinical evaluators. 
CMAP amplitude is an electrophysiological technique that
eflects the mass of excitable muscle tissue depolarized
ith whole nerve stimulation, and in SMA relates to the
pproximate number of motor neurons innervating a muscle.
lnar CMAP amplitude is a well-validated method for
racking disease progression in SMA [32 , 33] . 
Measurement of growth parameters included length, 
eight-for-age, length-for-age, weight-for-length, head 
ircumference, chest circumference, head-to-chest 
ircumference ratio, and arm circumference. WHO child
rowth standards were used to determine percentiles for each
arameter [28] . 
pNF-H levels recently have been shown to be a potential
iomarker of disease severity and response to treatment in
ndividuals with SMA. Plasma and CSF samples were tested
or pNF-H. pNF-H levels were summarized as geometric
ean for NURTURE infants by SMN2 copy number and
ompared with levels reported for infants without SMA aged
 1 year. Geometric mean was used to appropriately account
or the underlying distribution of the data. Samples from
8 individuals were donated by Boston Children’s Hospital
Boston, MA) and confirmed to be from individuals with
o known neurological or musculoskeletal disorders or other
hronic illness. pNF-H levels were measured using a pNF-H
nzyme-linked lectin assay from ProteinSimple. 
Safety assessments included treatment-emergent 
E monitoring, neurological examinations, physical 
xaminations, vital sign measurements, pulse oximetry,
2-lead ECGs, and laboratory testing (hematology, blood
hemistry, urinalysis, and coagulation) and were performed
y trained physicians and ancillary medical professionals. 
.4. Sibling assessments 
When possible, comparisons in survival and motor
ilestone achievement were made between NURTURE 
articipants and non-nusinersen-treated siblings with SMA.
nly non-invasive data were collected from siblings,
ncluding SMN2 gene copy number, sibling SMA history, and
ibling treatment history. .5. Statistical methods 
Time to death or respiratory intervention, proportion
f participants alive, proportion of participants achieving 
HO motor milestones, proportion of participants developing 
linically manifested SMA, and safety analyses were analyzed
n all study participants who received ≥1 dose of nusinersen
intent-to-treat population). All other efficacy analyses were
erformed on interim efficacy sets that comprised all
osed participants who attended or had the opportunity
o attend the targeted visit of the analysis (efficacy set).
ll secondary endpoints were assessed at ages 13 and 24
onths. Proportion of participants alive and proportion who
chieved WHO motor milestones at ages 13 and 24 months
ere estimated using the Kaplan-Meier method. CHOP
NTEND total score, HINE-2 total motor milestone score,
hange in growth parameters, ulnar and peroneal CMAP
mplitude, and pNF-H concentrations were summarized 
sing descriptive statistics. The proportion of participants
eveloping clinically manifested SMA at Day 365 (13-month
ssessment) or Day 700 (24-month assessment) were reported
ith a corresponding Wilson score confidence interval (CI)
ith continuity correction [34] . The age at which a WHO
otor milestone was achieved was determined by using the
aregiver-reported date if confirmed at the subsequent study
isit by the physical therapist. 
To identify early predictors of motor function, Spearman
orrelation coefficients were calculated. Specifically, the 
elationships between participant characteristics at baseline 
nd at the end of the loading dose period on Day 64 (age at
rst dose of nusinersen, gestational age, plasma pNF-H levels,
eight for age, CHOP INTEND total score, HINE-2 motor
ilestone total score, and ulnar CMAP amplitude) and future
otor function (Day 302 total HINE-2 motor milestone score
nd age of achievement of walking alone) were evaluated. The
tatistical software SAS R © version 9.4 (Cary, NC) or above
as used for all summaries and statistical analyses. 
. Results 
.1. Study population 
A total of 30 infants were screened; 25 infants (15 with two
MN2 copies and 10 with three SMN2 copies) met eligibility
riteria and were enrolled in the study. Five infants were
neligible; one did not have a diagnosis of 5q SMA, one did
ot have two or three copies of the SMN2 gene, and three
ad an ulnar CMAP amplitude equal to or below one mV at
creening (two of whom also had clinical signs or symptoms
uggestive of SMA). The first participant’s initial visit was in
ay 2015 and enrollment was complete in February 2017.
s of data cutoff, no participants have withdrawn from the
tudy or discontinued treatment. 
The median (range) age at first dose of nusinersen among
nrolled infants was 22.0 (3–42) days. At the time of the
nterim analysis, median (range) age at last visit was 34.8
25.7–45.4) months and time on study was 33.9 (25.3–45.1)
846 D.C. De Vivo, E. Bertini and K.J. Swoboda et al. / Neuromuscular Disorders 29 (2019) 842–856 
Table 1 
Baseline characteristics. 
Characteristic 2 SMN2 copies n = 15 a 3 SMN2 copies n = 10 Total N = 25 
Age at first dose, days, n (%) 
≤14 6 (40) 3 (30) 9 (36) 
> 14 and ≤28 7 (47) 5 (50) 12 (48) 
> 28 2 (13) 2 (20) 4 (16) 
Median (range) 19.0 (8–41) 23.0 (3–42) 22.0 (3–42) 
Mean (SD) 19.5 (9.29) 22.3 (12.45) 20.6 (10.51) 
Male, n (%) 8 (53) 4 (40) 12 (48) 
CHOP INTEND total score n = 15 n = 10 n = 25 
Median (range) 45.0 (25.0–60.0) 53.5 (40.0–60.0) 50.0 (25.0–60.0) 
Mean (SD) 47.0 (10.04) 51.9 (6.10) 49.0 (8.87) 
HINE total motor milestones n = 15 n = 10 n = 25 
Median (range) 3.0 (0–5) 3.0 (0–7) 3.0 (0–7) 
Mean (SD) 2.7 (1.59) 3.2 (1.87) 2.9 (1.69) 
Ulnar CMAP amplitude, mV n = 14 n = 10 n = 24 
Median (range) 2.30 (1.0–6.7) 2.90 (1.8–4.9) 2.65 (1.0–6.7) 
Mean (SD) 2.69 (1.516) 3.11 (1.119) 2.87 (1.354) 
Peroneal CMAP amplitude, mV n = 12 n = 10 n = 22 
Median (range) 3.20 (1.1–9.7) 4.00 (0.2–7.0) 3.30 (0.2–9.7) 
Mean (SD) 3.52 (2.159) 3.75 (2.188) 3.62 (2.123) 
Plasma pNF-H, pg/mL b n = 13 n = 9 n = 22 
Geometric mean (95% CI) 20880.9 (9639.4–45231.9) 1870.7 (1152.9–3035.5) 7782.7 (3828.6–15820.3) 
Range 845–52,900 959–7950 845–52,900 
CSF pNF-H, pg/mL b n = 14 n = 9 n = 23 
Geometric mean (95% CI) 20139.2 (10075.0–40256.7) 951.5 (366.5–2470.2) 6099.8 (2646.0–14062.0) 
Range 342–37,200 261–9140 261–37,200 
CHOP INTEND, Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders; CMAP, compound muscle action potential; CSF, cerebrospinal 
fluid; HINE, Hammersmith Infant Neurologic Examination; pNF-H, phosphorylated neurofilament heavy chain; SD, standard deviation; SMN2 , survival motor 
neuron 2. 
a Included one set of twins; each child had two SMN2 copies. 
b The number of decimal places reported in summary statistics is not indicative of biomarker assay precision or sensitivity. 
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tmonths. Baseline characteristics by SMN2 copy number
are shown in Table 1 . Median (range) CHOP INTEND
total score and total HINE-2 motor milestone scores were
45.0 (25.0–60.0) and 3.0 (0–5), respectively, in two-copy
participants ( n = 15) and 53.5 (40.0–60.0) and 3.0 (0–7),
respectively, in three-copy participants ( n = 10). Twenty-four
participants consented to collection of plasma and CSF
for future investigations of possible biomarkers of SMA
disease. Baseline plasma values were unavailable in two
participants, and baseline CSF values were unavailable
in one participant. Geometric mean (95% CI) plasma
pNF-H concentrations were 20,880.9 (9639.4–
45,231.9) pg/mL in two-copy participants ( n = 13), and
1870.7 (1152.9–3035.5) pg/mL in three-copy participants
( n = 9). Geometric mean (95% CI) CSF pNF-H concentrations
were 20,139.2 (10,075.0–40,256.7) pg/mL in two-copy
participants ( n = 14) and 951.5 (366.5–2470.2) pg/mL
in three-copy participants ( n = 9). Nineteen NURTURE
participants had ≥1 sibling with SMA; in total, there were
22 full siblings and two half siblings. Of the 24 siblings, eight
had two SMN2 copies, eight had three SMN2 copies, and
eight had an undocumented number of SMN2 copies. One of
the siblings was related to two NURTURE participants (a set
of twins). .2. Efficacy 
.2.1. Primary endpoint: survival and respiratory 
ntervention 
As of this interim analysis, all 25 NURTURE participants
ere alive and none required permanent ventilation. The
edian time to death or respiratory intervention (invasive
r non-invasive ventilation for ≥6 h/day continuously for
7 days or tracheostomy) could not be estimated, as there
ere too few events. Four (16%) infants (all with two SMN2
opies) utilized respiratory intervention for ≥6 h per day
ontinuously for ≥7 days ( Fig. 2 ), all of whom initiated
espiratory intervention during an acute, reversible illness. At
he last study day prior to data cutoff, two of these infants
o longer utilized respiratory intervention; these infants had
reviously received respiratory intervention for ≥6 h per day
or totals of 20 and 266 days during the course of the
tudy. The other two infants continued to receive respiratory
ntervention for two and 10 h per day, respectively, at the
ast study day prior to data cutoff; these infants received
espiratory intervention for ≥6 h per day for totals of 236 and
44 days, respectively, over the course of the study. No other
nfants received respiratory intervention during the course of
he study. 
D.C. De Vivo, E. Bertini and K.J. Swoboda et al. / Neuromuscular Disorders 29 (2019) 842–856 847 
Fig. 2. Kaplan–Meier plot for age at death or respiratory intervention. a 
SMN2 , survival motor neuron 2. 
No participants have died or required tracheostomy or permanent ventilation (defined as ≥16 h/day continuously for > 21 days in the absence of an acute 
reversible event or tracheostomy). 
a Respiratory intervention was defined as ventilator use for ≥6 h per day for ≥7 days or tracheostomy. 
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chievement of motor milestones. As of data cutoff, all
25/25; 100%) NURTURE infants achieved the WHO motor
ilestone “sitting without support”, while 23/25 (92%; 13/15
ith two SMN2 copies and 10/10 with three SMN2 copies)
chieved “walking with assistance”, and 22/25 (88%; 12/15
ith two SMN2 copies and 10/10 with three SMN2 copies)
chieved “walking alone”. Site- or caregiver-reported ages of
rst achievement for WHO motor milestones are shown in
ig. 3 . Most participants achieved these milestones within
he window established by the WHO for healthy children;
pecifically, 21/25 [84%] achieved sitting without support,
5/23 [65%] achieved walking with assistance, and 16/22
73%] achieved independent walking by the WHO 99th
ercentile age of achievement [28,35] . The median (95%
I) ages for first achievement of sitting without support,
alking with assistance, and walking alone in two SMN2
opy participants were 7.9 (5.9–9.2) months, 16.1 (11.8–
8.8) months, and 20.4 (15.5, 29.7) months, respectively. In
hose with three SMN2 copies, the median (95% CI) ages
or first achievement of sitting without support, walking with
ssistance, and walking alone were 6.4 (5.1–7.9) months, 9.6
8.0–11.8) months, and 12.3 (11.2–14.9) months, respectively.
HINE-2 motor milestone total scores also increased over
ime for all participants regardless of SMN2 copy number.
ean (range) total scores increased from a baseline of 2.7
0–5) to 23.9 (16–26) at the last observed visit, up to andncluding Day 778, for participants with two SMN2 copies
nd from 3.2 (0–7) to 26.0 (26–26) for those with three
MN2 copies. Mean scores for infants with two or three
MN2 copies approached the scale maximum of 26 points;
hree-copy participants approached the maximum earlier than
articipants with two SMN2 copies ( Fig. 4 ). 
otor function. Mean CHOP INTEND total scores rose
teadily from baseline until approximately Day 183 and then
emained stable over time ( Fig. 5 (A)). At the last visit, mean
range) CHOP INTEND total score was 62.1 (48–64) in those
ith two SMN2 copies and 63.4 (58–64) in those with three
MN2 copies. At the time of this interim analysis, 10/15
67%) of participants with 2 SMN2 copies and 10/10 (100%)
f those with 3 SMN2 copies had achieved a maximum score
f 64 ( Fig. 5 (B)). Beyond Day 183, CHOP INTEND total
cores appear to be constrained by a plateau ceiling effect
f ∼60 points and was no longer assessed after participants
ad achieved the maximum score of 64; however, continued
mprovement was observed in HINE-2 and WHO milestones
utcomes. 
At the last observed visit up to and including Day 778, all
URTURE participants had the ability to suck and swallow
s measured by the HINE-1 neurological assessment. Twenty-
wo participants (12/15 with two SMN2 copies, 10/10 with
hree SMN2 copies) achieved the maximum score of 3 (good
ucking and swallowing) on the HINE-1. Three infants (all
848 D.C. De Vivo, E. Bertini and K.J. Swoboda et al. / Neuromuscular Disorders 29 (2019) 842–856 
Fig. 3. Site- or caregiver-reported a age at first WHO motor milestone achievement. 
SMN2 , survival motor neuron 2; WHO, World Health Organization. 
a If caregiver-reported, achievement was confirmed by the study site at the next study visit with a yes or no response. 
b WHO motor milestone windows of achievement were determined based on the WHO Multicenter Growth Reference Study windows of achievement in healthy 
children [28] . 
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a  with two SMN2 copies) achieved a score of 1 (poor sucking
and/or swallowing); each of these three had gastrostomy tubes
placed. 
Clinically manifested SMA. The proportions of two SMN2
copy participants who had protocol-defined symptoms ofMA were 0.67 (95% CI 0.39–0.87; n = 10 of 15 total) at
ge 13 months and 0.47 (95% CI 0.22–0.73; n = 7 of 15
otal) at age 24 months. The proportions of three SMN2
opy participants who had protocol-defined symptoms of
MA were 0.20 (95% CI 0.04–0.56; n = 2 of 10 total) at
ge 13 months and 0.00 (95% CI 0.00–0.34; n = 0 of 10
D.C. De Vivo, E. Bertini and K.J. Swoboda et al. / Neuromuscular Disorders 29 (2019) 842–856 849 
Fig. 4. Mean HINE-2 motor milestone scores over time. 
HINE-2, Hammersmith Infant Neurologic Examination, Section 2; SE, standard error; SMN2 , survival motor neuron 2. 
Time points with n ≥5 included. HINE-2 score was assessed in NURTURE participants up until the Day 778 study visit. 
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(  otal) at age 24 months. The seven infants who developed
rotocol-defined symptoms of SMA by 24 months (all with
wo SMN2 copies) were all continuing to grow and achieve
HO motor milestones inconsistent with Type I SMA and
ith the milestone attainment of their siblings with SMA. All
even were sitting without support, five were walking with or
ithout assistance, and four were walking alone. Six of these
even participants had siblings with SMA; none of the siblings
chieved sitting independently and 5/6 required tracheostomy
nd/or died by 16 months of age. 
The seven infants with clinically manifested SMA at
ge 24 months included the three participants with a poor
uck/swallow reflex who had gastrostomy tubes placed. While
hese three infants undoubtedly exceeded their expected two
MN2 copy Type I predicted phenotype by achieving the
bility to sit independently, they achieved motor milestones
t a slower pace than other participants with two SMN2
opies in the study. All three participants were able to stand
ith assistance, two were able to walk with assistance, and
ne achieved walking alone; two were infants who received
espiratory intervention at last visit. 
.2.3. Exploratory endpoints 
hange in pNF-H over time. Baseline pNF-H levels were
igher in most presymptomatic infants with SMA compared
ith non-SMA infants and were significantly higher in most
articipants with two SMN2 copies compared with those with
hree SMN2 copies (plasma P = 0.0050; CSF P = 0.0020). The
eometric mean plasma pNF-H level in healthy infants < 1
ear of age was 1090.8 pg/mL (median 1007.4 [range 293–
033] pg/mL; n = 18; Fig. 6 (A)). In presymptomatic infants
ith SMA, geometric mean plasma pNF-H levels declinedapidly during the loading phase of nusinersen treatment
nd then stabilized ( Fig. 6 (B)). A similar pattern of decline
ollowed by stabilization was observed for geometric mean
SF pNF-H levels (Supplementary Fig. 1). 
MAP. Mean (standard deviation [SD]) ulnar nerve CMAP
mplitudes at baseline were 2.69 (1.52) mV and 3.11
1.12) mV in participants with two and three SMN2 copies,
espectively ( P = 0.2895), and remained stable over time
Supplementary Fig. 2(A)). Similar results were observed for
eroneal nerve to tibialis anterior CMAP amplitude (baseline
eroneal CMAP amplitude in two versus three SMN2 copy
articipants, P = 0.4755; Supplementary Fig. 2(B)) 
.3. Predictors of future motor function achievements 
Correlations were calculated to identify the earliest,
trongest predictors of motor function. Among the baseline
haracteristics analyzed, baseline plasma pNF-H level was
he strongest predictor of HINE-2 total motor milestone
core at Day 302 ( r s = −0.53; P = 0.0120; n = 22) and age of
chievement of WHO walking alone ( r s = 0.55; P = 0.0147;
 = 19). In the analysis of participant characteristics at Day
4, plasma pNF-H levels at Day 64 were the best predictor of
uture motor function achievement in the overall population.
lasma pNF-H levels at Day 64 were significantly correlated
ith the total HINE-2 motor milestone score at Day 302
 r s = −0.67; P = 0.0005; n = 23) and with achievement
f the WHO motor milestone walking alone ( r s = 0.64;
 = 0.0025; n = 20). Lower plasma pNF-H levels at day 64
ere associated with earlier achievement of walking alone
 Fig. 7 ). In participants with 2 SMN2 copies, Day 64 weight
850 D.C. De Vivo, E. Bertini and K.J. Swoboda et al. / Neuromuscular Disorders 29 (2019) 842–856 
Fig. 5. (A) Mean CHOP INTEND score over time, (B) Kaplan–Meier plot for time to first achievement of maximum CHOP INTEND score of 64 points. a 
CHOP INTEND, Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders; SE, standard error; SMN2 , survival motor neuron 2. 
For Fig. 5 (A), time points with n ≥5 included. a In the original protocol, CHOP INTEND was to be assessed in participants at each visit up to Day 778; 
however, this was amended to be until they had a maximum score of 64. Once a score of 64 was achieved, CHOP INTEND was no longer assessed. 
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p  for age ( r s = 0.72; P = 0.0027; n = 15) and Day 64 CMAP
amplitude ( r s = 0.66; P = 0.0098; n = 14) were correlated
with total HINE-2 motor milestone achievement at Day 302,
and similar results were observed for age at achievement
of WHO walking alone. The associations between Day 64
weight for age or Day 64 CMAP amplitude and achievement
of WHO walking alone are shown in Supplementary
Figs. 3(A) and 3(B). 
Plasma pNF-H levels at Day 302 were evaluated in
relationship to those from individuals without SMA and to
motor milestone achievement and other outcomes. Plasma
samples were analyzed from 18 non-SMA individuals who
ranged in age from 0.15 to 0.91 years. These individuals
had plasma pNF-H levels ranging from 293 to 7033 pg/mL
(Q1, 616 pg/mL; Q3, 1753 pg/mL). NURTURE Day 302 was
selected for this analysis based on the age range of non-MA individuals. Twenty-two NURTURE participants had a
ecorded measurement for Day 302 plasma pNF-H level, 13
f whom (3 with 2 SMN2 copies; 10 with 3 SMN2 copies) had
 result below Q3 ( ≤1753 pg/mL) for non-SMA individuals
 1 year of age. Among these 22 NURTURE participants,
ll children who initiated ventilation support ( n = 4), met the
rotocol definition of clinically manifested SMA at Day 700
 n = 6), and/or had delayed (or no) achievement of sitting or
alking alone (per WHO 99th percentile window) had a Day
02 plasma pNF-H level above the Q3 ( > 1753 pg/mL) for
on-SMA individuals < 1 year of age. 
.4. Safety 
AEs were reported in 25/25 (100%) NURTURE
articipants ( Table 2 ). Twenty of 25 (80%) participants
D.C. De Vivo, E. Bertini and K.J. Swoboda et al. / Neuromuscular Disorders 29 (2019) 842–856 851 
Fig. 6. (A) Plasma pNF-H levels at baseline in NURTURE infants and infants < 1 year of age without SMA, (B) plasma pNF-H levels in NURTURE infants 
by study visit. a 
CI, confidence interval; ELLA, enzyme-linked lectin assay; pNF-H, phosphorylated neurofilament heavy chain; SMA, spinal muscular atrophy; SMN2 , survival 
motor neuron 2. 
pNF-H levels were evaluated using a pNF-H ELLA from ProteinSimple. 7.46 pg/mL was used as the imputed value if the pNF-H concentration was below 
the limit of quantification. Baseline pNF-H values in NURTURE infants were obtained on Study Visit Day 1, either prior to nusinersen administration or four 
h post-dose. Samples from infants without SMA were provided by Boston Children’s Hospital. 
a Time points with n ≥5 included. The number of decimal places reported in summary statistics is not indicative of biomarker assay precision or sensitivity. 
In Panel A, some data points have an x -value offset of + / −0.2 months for better visualization. 
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dad an AE that was mild or moderate in severity. There were
o AEs considered to be definitely related to study drug
y the investigators. All AEs considered by the investigator
o be possibly related to study drug (8/25 infants; 32%)
esolved despite continued treatment, with the exception
f one case each of proteinuria and clonus, which were
ngoing at the time of data cutoff. A total of 33 SAEs were
eported in 12/25 (48%) participants. Treatment-emergent 
AEs in those 12 participants included tendon disorder
nd dehydration ( n = 1); bronchitis, choking, pneumonia
 n = 1); pneumonia ( n = 1); mycoplasmal pneumonia ( n = 1);
iral upper respiratory tract infection ( n = 1); abdominalistension, respiratory distress, dehydration, enterovirus 
nfection, corona virus infection, respiratory syncytial 
irus bronchiolitis, bacterial pneumonia, acute respiratory 
ailure, respiratory failure, tachycardia, viral gastroenteritis, 
neumonia ( n = 1); respiratory distress, respiratory syncytial
irus bronchiolitis, aspiration pneumonia, pneumonia ( n = 1);
ailure to thrive ( n = 1); urinary tract infection ( n = 1);
yrexia, pneumonia, pneumococcal pneumonia, pseudomonal 
neumonia, upper respiratory tract infection ( n = 1);
espiratory syncytial virus infection ( n = 1); upper respiratory
ract infection ( n = 1). There were no SAEs related to study
rug. 
852 D.C. De Vivo, E. Bertini and K.J. Swoboda et al. / Neuromuscular Disorders 29 (2019) 842–856 
Fig. 7. Plasma pNF-H levels at Day 64 and achievement of WHO motor milestone of walking alone 
pNF-H, phosphorylated neurofilament heavy chain; SMN2 , survival motor neuron 2; WHO, World Health Organization. 
1 WHO 99th percentile for age of achievement for development in healthy children [28] . 
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s  The lumbar puncture procedure was generally well
tolerated. Eight participants had an event determined by
investigators to be possibly related or definitely related
to the lumbar puncture procedure: traumatic lumbar
puncture ( n = 1); vomiting ( n = 1); subdural hematoma,
post-procedure discomfort ( n = 1); headache ( n = 1); post-
lumbar puncture procedure syndrome, lower lumbar spinal
canal hematoma, hypertension ( n = 1); post-procedural
swelling ( n = 1); extradural hematoma, tachycardia, weight-
bearing difficulty, muscular weakness ( n = 1); and epidural
hemorrhage, spinal subarachnoid hemorrhage, tachycardia,
hyperreflexia ( n = 1). Five hemorrhages near the thecal space
in four participants occurred in the setting of multiple lumbar
puncture attempts; all events occurred when participants
were < 6 weeks old, and none were in the context of
thrombocytopenia. The only lumbar puncture-related event
classified as an SAE was one case of post-lumbar puncture
syndrome that occurred before the first dose of study drug
following a failed dosing attempt. 
No clinically relevant trends with respect to
thrombocytopenia, coagulation abnormalities, abnormal liver
and kidney function tests, or proteinuria were observed in the
NURTURE cohort. There were no observed cases of heart
disease, liver failure, bacterial meningitis, aseptic meningitis,
hypersensitivity, or hydrocephalus. Alanine aminotransferase
(ALT), aspartate aminotransferase (AST), creatine kinase,reatinine, cystatin C, and platelet levels remained stable
ver time (Supplementary Figs. 4–8). 
. Discussion 
To our knowledge, NURTURE is the first study to
nvestigate a treatment targeting the underlying cause of the
MA disease in a presymptomatic period and one of the first
wo studies to investigate any treatment for presymptomatic
MA [36] . The results of this interim analysis, representing
 median 2.9 years of follow up, demonstrate substantial
linical benefit in infants with two or three copies of the
MN2 gene (considered most likely to develop Type I
r II SMA) as a result of early initiation of nusinersen
reatment. NURTURE infants, who at the time of this
nterim analysis were age ≥25 months and past the age of
ymptom onset [3 , 27] , were all alive without requirement
or permanent ventilation. The contrast to the natural history
f untreated SMA is dramatic: those with SMA Type I
the expected phenotype for approximately half our cohort
ased on SMN2 copy number) die or require permanent
entilation, on average, by 13.5 months of age [27] . That
arly treatment is key to this rescue arises from comparison
f the NURTURE experience with that of the ENDEAR
tudy, in which treatment with nusinersen was initiated in a
ymptomatic period. By the end of the ENDEAR study, 31/80
D.C. De Vivo, E. Bertini and K.J. Swoboda et al. / Neuromuscular Disorders 29 (2019) 842–856 853 
Table 2 
Summary of safety. 
AE, n (%) 2 SMN2 copies n = 15 3 SMN2 copies n = 10 Total N = 25 
Any AE 15 (100) 10 (100) 25 (100) 
Serious AE 9 (60) 3 (30) 12 (48) 
Severe AE 5 (33) 0 5 (20) 
AE related to study drug a 0 0 0 
AE possibly related to study drug a 4 (27) 4 (40) 8 (32) 
Proteinuria 1 (7) 1 (10) 2 (8) 
Increased alkaline phosphatase and calcium 1 (7) 0 1 (4) 
Muscular weakness, weight-bearing difficulty, extensor plantar response, clonus 1 (7) 0 1 (4) 
Hyperreflexia and tachycardia 0 1 (10) 1 (4) 
Pyrexia, increased ALT, increased AST, increased eosinophil, lymphocyte, and 
WBC counts 
1 (7) 0 1 (4) 
Increased platelet count 0 1 (10) 1 (4) 
Rash 0 1 (10) 1 (4) 
Serious AE related to study drug a 0 0 0 
AE possibly related to lumbar puncture procedure b 6 (40) 2 (20) 8 (32) 
AE leading to treatment discontinuation or study withdrawal 0 0 0 
Incidence of AEs by MedDRA PT occurring in ≥5 participants 
Pyrexia 14 (93) 7 (70) 21 (84) 
Upper respiratory tract infection 12 (80) 7 (70) 19 (76) 
Cough 8 (53) 5 (50) 13 (52) 
Nasopharyngitis 9 (60) 4 (40) 13 (52) 
Vomiting 7 (47) 3 (30) 10 (40) 
Fall 4 (27) 5 (50) 9 (36) 
Rhinorrhea 5 (33) 4 (40) 9 (36) 
Nasal congestion 5 (33) 3 (30) 8 (32) 
Otitis media 4 (27) 4 (40) 8 (32) 
Diarrhea 2 (13) 5 (50) 7 (28) 
Influenza 4 (27) 3 (30) 7 (28) 
Seasonal allergy 3 (20) 4 (40) 7 (28) 
Tremor 7 (47) 0 7 (28) 
Anemia 3 (20) 3 (30) 6 (24) 
Constipation 5 (33) 1 (10) 6 (24) 
Dehydration 5 (33) 1 (10) 6 (24) 
Pneumonia 6 (40) 0 6 (24) 
Diaper dermatitis 3 (20) 2 (20) 5 (20) 
Viral gastroenteritis 3 (20) 2 (20) 5 (20) 
Muscular weakness 5 (33) 0 5 (20) 
Tachycardia 4 (27) 1 (10) 5 (20) 
AE, adverse event; ALT, alanine aminotransferase, AST, aspartate aminotransferase; MedDRA PT, Medical Dictionary for Regulatory Activities Preferred 
Term; SMN2 , survival motor neuron 2. 
Values refer to numbers and percentages of study participants. 
a Assessed by the investigator. 
b Assessed by the investigator; includes events that are possibly related or related to the LP procedure. 
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S  39%) nusinersen-treated infants with infantile-onset SMA
ied or required permanent ventilation [8] . All NURTURE
articipants are alive without permanent ventilation and able
o sit independently; nearly all children (23/25) can walk
ith assistance or independently, and all continued to gain
otor skills throughout the study interval. In both groups of
hildren with two and three SMN2 copies, nusinersen showed
apid onset of improvement and durability of effect on mean
HOP INTEND motor function scores. These results are
learly incongruent with the natural history of individuals
ith two or three copies of SMN2 [6] . These results
emonstrate that treatment with nusinersen of genetically
iagnosed infants with SMA in the presymptomatic period
llows for gains in motor function closer to normal
evelopment than that expected in individuals with SMA
ype I or II. The motor milestone and motor function achievements of
any NURTURE infants are also drastically discordant from
heir untreated siblings with the same SMN2 copy number.
his discordance is notable, given that a previous study found
hat 86.8% of 265 sibling pairs with SMA had a concordant
henotype [26] , further emphasizing the clinically meaningful
enefit of nusinersen treatment in the presymptomatic period.
HOP INTEND scores for NURTURE infants were similar
o those observed for healthy infants over the first three
tudy months, the interval for which natural history data on
ealthy infants are available [37] . NURTURE infants’ CHOP
NTEND scores greatly exceed those observed in a natural
istory cohort of symptomatic infants with SMA with two
opies of SMN2 over the course of the study, who had a mean
SD) decline of 10.71 (9.43) points over 6–12 months [37] .
imilarly, the mean ulnar CMAP amplitude of NURTURE
854 D.C. De Vivo, E. Bertini and K.J. Swoboda et al. / Neuromuscular Disorders 29 (2019) 842–856 
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a  infants remained stable over time in participants with two
and three SMN2 copies in NURTURE, while amplitude fell
rapidly and was never higher than 0.6 mV in a natural history
cohort of infants with SMA aged ≥6 months with two SMN2
copies [37] . 
Overall, the NURTURE infants who initiated treatment
before the appearance of clinical symptoms had earlier and
substantially greater improvement in HINE-2 total scores
than did infants and children who initiated treatment after
symptom onset in the ENDEAR and CS3a trials [8 , 25] .
NURTURE infants also had higher baseline CHOP INTEND
scores and were able to attain maximum or near-maximum
CHOP INTEND scores more quickly than did infants who
initiated treatment after symptom onset [8 , 25] . While the
differences in population ages and study designs between
studies must be kept in mind when interpreting these data, the
differences in HINE-2 score trajectories and CHOP INTEND
maximum scores indicate that treatment with nusinersen can
have a meaningful impact on clinical outcome beyond that
seen when treatment is initiated after symptom onset. 
The functional outcomes of NURTURE participants with
three SMN2 copies were generally better than those observed
in participants with two copies of SMN2 . Specifically, all
participants with three SMN2 copies have achieved all of the
more advanced WHO motor milestones, including walking
independently; whereas three participants with two SMN2
copies have yet to achieve these milestones. Participants
with three SMN2 copies also achieved higher mean CHOP
INTEND and HINE-2 total scores by last observed visit than
participants with two SMN2 copies. Baseline CHOP INTEND
and HINE-2 scores were also higher in participants with
three SMN2 copies versus two SMN2 copies. While slight
differences in the outcomes of patients with three SMN2
copies and two SMN2 copies were observed, all far exceed
outcomes predicted by SMA Type I and II natural history. 
These findings highlight the substantial benefit of early
therapy, and thus point to the value of early diagnosis.
Population-based newborn screening (NBS) is a method for
identifying presymptomatic individuals with treatable diseases
that aims to provide the opportunity for early intervention
[16] . In the United States, NBS for homozygous deletion of
exon 7 in the SMN1 gene was added to the Recommended
Uniform Screening panel (RUSP) on July 16th, 2018.
Other NBS programs are in development globally [17–
20] . Presymptomatic individuals with SMA are now being
identified in several US states through NBS programs, and
many additional states will begin screening later in 2019.
Additional NBS efforts for SMA are ongoing globally and
are supported by the general population in several countries
[17–19 , 38 , 39] . A treatment algorithm based on SMN2 copy
number for SMA positive infants identified though NBS was
recently developed by a group of SMA experts [40] . The
recommendation was for infants with two or three SMN2
copies to receive immediate treatment following confirmatory
testing. An additional recommendation by other SMA experts
suggests immediate treatment for presymptomatic infants
with up to four SMN2 copies [41] . NURTURE resultsupport immediate treatment of infants with two or three
MN2 copies and support the notion that earlier treatment
cross the spectrum improves eventual outcome as was
emonstrated by the ENDEAR and CHERISH studies [8 , 9] . 
pNF-H levels recently have been shown to be a potential
iomarker of disease severity and response to treatment in
ndividuals with SMA. Concentrations of pNF-H in both the
NDEAR and CHERISH studies were found to correlate
ith several baseline clinical characteristics indicative of
isease severity and decline rapidly after treatment with
usinersen before stabilizing at lower plateau levels [13] . To
ur knowledge, NURTURE is the first study to evaluate pNF-
 levels in a presymptomatic SMA population. Geometric
ean plasma and CSF levels of pNF-H were substantially
igher in NURTURE participants than in infants without
MA and, within NURTURE participants, plasma and CSF
NF-H levels were significantly higher in participants with
wo versus three SMN2 copies. After nusinersen treatment
nitiation, pNF-H levels declined rapidly during the loading
eriod before apparently stabilizing at lower levels. The rapid
ecline of pNF-H levels suggests the value of pNF-H as a
otential biomarker of treatment response to SMN-enhancing
herapies. Levels of pNF-H in plasma at the end of the
usinersen loading dose period may predict future motor
unction such as walking alone by the WHO 99th percentile
or expected age of achievement. 
The very high pNF-H levels measured before onset of
linical symptoms suggest that pathophysiologic processes
recede the onset of clinical symptoms; whether release of
NF-H into interstitial fluids marks a treatment-reversible
athology, or instead an early degeneration that is not yet
f sufficient magnitude to be clinically apparent, is yet
nknown. In either case, pre-treatment elevation of pNF-H
evels in these presymptomatic infants further emphasizes the
alue of NBS initiatives worldwide and stress the importance
f proactive intervention in the presymptomatic phase of
MA, consistent with other chronic progressive neurological
iseases [42–45] . 
Nusinersen demonstrated a favorable benefit-risk profile
onsistent with data from previous studies [8 , 9] and no
ew safety concerns were identified. The lumbar puncture
rocedure was generally well tolerated. A small number of
emorrhages near the thecal space occurred in the setting of
ultiple LP attempts in infants who were < 6 weeks old; none
ere in the context of thrombocytopenia. Careful monitoring
f hematology, blood chemistry, urinalysis, coagulation, vital
igns, and ECGs demonstrated no clinically relevant trends
elated to nusinersen treatment. Levels of creatine kinase and
ransaminases (ALT and AST) remained stable over time,
uggesting no predisposition to muscle injury and no hepatic
bnormalities. 
Though the NURTURE outcomes are dramatic, key
imitations of the study should be noted. NURTURE is
n open-label study with a relatively small number of
articipants. While several participants had untreated siblings
ith SMA that allowed for the comparison of motor function
chievement with natural history, formal assessments were
D.C. De Vivo, E. Bertini and K.J. Swoboda et al. / Neuromuscular Disorders 29 (2019) 842–856 855 
n  
h  
h  
(  
H  
o  
a  
t  
u  
a  
e  
s  
u  
A  
a  
d  
i  
c
v  
m  
a  
p  
o  
d
5
 
p  
p  
i  
t  
i  
d  
o  
t  
T  
n  
s  
e  
a  
N  
i  
m  
t  
t  
i  
w  
S  
r
A
 
t  
w  
t  
t  
c
B  
t  
A  
fi  
N
a  
a  
p
D
 
s  
b
S
 
f  
0
R
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[  
 
 
 
[  
 
 
[  
 
 
 ot performed in the siblings with SMA, and the study
as no sham-control group. It should be noted that infants
ad variable presentation across clinical measures at baseline
notably tendon reflexes, ulnar CMAP, and CHOP-INTEND).
owever, although there is no uniformly established definition
f SMA symptom onset, all infants met the entry criteria
nd were considered presymptomatic at enrollment according
o the investigator. CHOP INTEND score was assessed
ntil a participant achieved the maximum score of 64,
fter which time it was no longer assessed, but a ceiling
ffect of the CHOP INTEND score was apparent at a
core of approximately 60. HINE-2 score was assessed
ntil Day 778 but was not assessed at later study visits.
dditionally, comparisons of changes in CHOP INTEND
nd HINE-2 scores over time across the nusinersen clinical
evelopment program must be made cautiously; differences
n study populations and study designs should be taken into
onsideration when interpreting the data. Caregiver-reported 
ersus study visit documentation of achievement of motor
ilestones could lead to variation in the reported timing of
chievements. Additionally, time of follow-up varies among
articipants, and first achievement of motor milestones may
ccur between study visits where these are assessed and
ocumented. 
. Conclusions 
Results from the NURTURE study demonstrate the
otential benefits of initiating nusinersen during the
resymptomatic period in infants with SMA. In this
nterim analysis, many infants and children treated during
he presymptomatic period achieved motor milestones
n timelines consistent with normal development. Data
emonstrate durability of effect over a median of 2.9 years
f follow up, with children continuing to make progress
hroughout the study with no evidence of sustained regression.
hese results not only exceed expectations based on the
atural history of SMA and the phenotypes of participants’
iblings with SMA, but also represent treatment benefits
xceeding those observed when treatment is initiated in
 symptomatic period. Additionally, pNF-H data from
URTURE demonstrate that the underlying SMA disease
s biologically active in the presymptomatic period and
erits treatment. Results from NURTURE strongly emphasize
he need for early identification of infants with SMA
hrough NBS and support the value of treatment initiation
n presymptomatic infants, genetically diagnosed with SMA
ith two or three copies of the SMN2 gene, immediately after
MA diagnosis. This conclusion is consistent with current
ecommendations [40 , 41] . 
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